GLP-1 and SGLT2 Combo Cuts Mortality 29% in T2D Study

In a significant advancement for GLP-1 and SGLT2 combination therapy in type 2 diabetes (T2D), new research from a large German health database demonstrates reduced all-cause mortality and select cardiovascular outcomes. Combined treatment with both a GLP-1 receptor agonist (GLP-1RA) and an SGLT2 inhibitor was linked to a 29% lower risk of death compared to SGLT2 inhibitors alone, offering potential clinical advantages in real-world practice.

Study Overview: Real-World Data from Germany

The study, published online in Diabetes, Obesity and Metabolism, analyzed data from 220,043 individuals who initiated SGLT2 inhibitors between 2013 and 2023, with follow-up through 2024. Of these, 2,660 were using GLP-1RAs at baseline, while 22,781 of the remaining 217,383 later received a GLP-1RA. After propensity score matching, researchers compared 21,664 combination users (SGLT2i + GLP-1RA) to an equal number of SGLT2i-only users over a median follow-up of 1.3 years. The primary outcome was all-cause mortality.

Gregor A. Maier, MSc, from the Institute for Biometrics and Epidemiology at the German Diabetes Center in Düsseldorf, Germany, and colleagues noted: "These findings suggest that sustained concurrent use of both drug classes may offer meaningful clinical advantages in routine practice, though the findings for specific secondary outcomes warrant further investigation."

Key Findings: Mortality and Cardiovascular Benefits

Combination therapy demonstrated clear advantages:

• All-cause mortality: 29% lower risk (hazard ratio [HR], 0.71 [95% CI, 0.63-0.80]; incidence rate [IR], 13.4 vs 18.6 per 1000 person-years [py]).
• Cardiovascular composite outcome: Lower risk (HR, 0.81 [95% CI, 0.74-0.88]; IR, 24.4 vs 29.9 per 1000 py).
• Heart failure: Reduced risk (HR, 0.78 [95% CI, 0.68-0.89]; IR, 10.0 vs 12.2 per 1000 py).

Secondary outcomes showed trends favoring combination therapy, including myocardial infarction (HR, 0.95; IR, 6.2 vs 6.5 per 1000 py) and stroke (HR, 0.86; IR, 6.1 vs 6.9 per 1000 py), though not statistically significant. Nephropathy was slightly higher (HR, 1.23; IR, 1.0 vs 0.8 per 1000 py), but renal failure was lower (HR, 0.9; IR, 3.2 vs 3.4 per 1000 py); neither reached significance. Effects were consistent across subgroups and sensitivity analyses.

The researchers highlighted alignment with UK data showing a 27% lower mortality risk (HR, 0.73; 95% CI, 0.52-1.01), primarily in poorly controlled diabetes (HbA1c > 8%). Notably, similar benefits appeared in this German cohort with better glycemic control, suggesting broader applicability.

Most Common Drug Combinations

The top prescribed pairings were:

• Dulaglutide plus empagliflozin (25%)
• Dulaglutide plus dapagliflozin (24%)
• Semaglutide plus dapagliflozin (18%)
• Semaglutide plus empagliflozin (14%)

How GLP-1RAs and SGLT2 Inhibitors Work Together

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and dulaglutide (Trulicity) mimic incretin hormones to enhance insulin secretion, slow gastric emptying, and promote satiety, aiding glycemic control and weight loss. SGLT2 inhibitors such as empagliflozin (Jardiance) and dapagliflozin (Farxiga) block glucose reabsorption in the kidneys, promoting urinary glucose excretion, which lowers blood sugar, reduces blood pressure, and protects the heart and kidneys.

Biologically, these classes offer complementary cardioprotection: GLP-1RAs reduce inflammation and improve endothelial function, while SGLT2is provide hemodynamic benefits and natriuresis. Their synergy in GLP-1 SGLT2 combination for T2D likely drives the observed outcomes, beyond glycemic effects alone.

Expert Commentary on Synergy and Cautions

"Biologically, GLP-1RAs and SGLT2 inhibitors provide cardio protection through different mechanisms, so their synergy is plausible."

— Richeek Pradhan, MD, PhD, assistant professor at the Centre for Medicine Use and Safety, Monash University, Australia.

Pradhan added to Medscape Medical News: "This paper adds to the evidence that combination of these meds may provide benefits in addition to the use of SGLT2 inhibitors alone, though we have to be careful about the observational nature of the current literature and lack of evidence regarding potential harms of such combinations."

He emphasized access barriers: In some systems, GLP-1RAs are restricted to treatment failures, and high costs may limit combinations. Treatment must be personalized, as frail patients at high cardiovascular risk could face compounded side effects like gastrointestinal issues from GLP-1RAs or dehydration from SGLT2is. Future research should examine risks.

Potential Benefits and Harms in Context

While observational, this study builds on randomized trials like EMPA-REG OUTCOME and LEADER, which established individual benefits. Combinations may enhance outcomes in T2D with cardiovascular disease (CVD), a leading cause of death. However, common GLP-1RA side effects include nausea and vomiting; SGLT2is risk genital infections and ketoacidosis. Monitoring is essential, especially in older or frail patients.

For patients, discuss combo therapy with your doctor if you have T2D and CVD risk factors. Tools like Shotlee can help track symptoms, side effects, or medication adherence during trials.

Clinical Implications for Patients and Providers

Who might benefit? Those with T2D and established CVD, heart failure, or chronic kidney disease, per guidelines from the American Diabetes Association. Start with monotherapy if tolerated, escalating to combinations based on response and tolerance. Compare to alternatives: Metformin remains first-line, but GLP-1RA/SGLT2i combos outperform in cardiorenal protection.

Providers should weigh costs, insurance, and patient frailty. Personalized decisions integrate A1c, weight, and comorbidities.

Key Takeaways

• Combination GLP-1RA + SGLT2i linked to 29% lower all-cause mortality vs SGLT2i alone in real-world T2D data.
• Significant reductions in CV composite and heart failure; trends for MI and stroke.
• Common combos: Dulaglutide/empagliflozin, semaglutide/dapagliflozin.
• Synergistic mechanisms, but observational limits and harm data needed.
• Personalize therapy; monitor for side effects.

Conclusion: Actionable Insights for Better T2D Management

This German study underscores the promise of GLP-1 and SGLT2 drugs in T2D for mortality and CV risk reduction, aligning with global evidence. Patients: Share CVD history with your endocrinologist to explore options. Providers: Consider combos in high-risk cases while awaiting RCTs. Stay informed on evolving guidelines for optimal metabolic health.